share_log

10-K: FY2024 Annual Report

10-K: FY2024 Annual Report

10-K：2024財年年報
美股SEC公告 ·  2024/09/30 19:33

Moomoo AI 已提取核心訊息

Incannex Healthcare reported a net loss of $18.5 million for fiscal year 2024, compared to $48.8 million in FY2023. Research and development expenses increased significantly to $12.9 million from $6.3 million, primarily due to the advancement of clinical trials for IHL-42X, IHL-675A, and PSX-001. The company received $11.4 million in R&D tax incentives, up from $0.7 million in the previous year.General and administrative expenses rose to $17.2 million from $8.0 million, driven by increased personnel costs, compliance expenses, and stock-based compensation. As of June 30, 2024, the company held cash and cash equivalents of $5.9 million, down from $22.1 million year-over-year, with current assets exceeding current liabilities by $10.6 million.The company has secured potential funding through a $50 million equity line of credit agreement with Arena Business and a convertible debenture arrangement for up to $10 million. Management believes these financing options, combined with current resources, should fund operations until August 2025, though substantial doubt exists about the company's ability to continue as a going concern beyond the next twelve months.
Incannex Healthcare reported a net loss of $18.5 million for fiscal year 2024, compared to $48.8 million in FY2023. Research and development expenses increased significantly to $12.9 million from $6.3 million, primarily due to the advancement of clinical trials for IHL-42X, IHL-675A, and PSX-001. The company received $11.4 million in R&D tax incentives, up from $0.7 million in the previous year.General and administrative expenses rose to $17.2 million from $8.0 million, driven by increased personnel costs, compliance expenses, and stock-based compensation. As of June 30, 2024, the company held cash and cash equivalents of $5.9 million, down from $22.1 million year-over-year, with current assets exceeding current liabilities by $10.6 million.The company has secured potential funding through a $50 million equity line of credit agreement with Arena Business and a convertible debenture arrangement for up to $10 million. Management believes these financing options, combined with current resources, should fund operations until August 2025, though substantial doubt exists about the company's ability to continue as a going concern beyond the next twelve months.
Incannex Healthcare在2024財年報告淨虧損1850萬澳元，而2023財年爲4880萬澳元。研發費用顯著增加至1290萬澳元，較去年的630萬澳元大幅提升，這主要是由於IHL-42X、IHL-675A和PSX-001臨牀試驗的推進。公司獲得了1140萬澳元的研發稅收激勵，較去年70萬澳元有所增加。一般和管理費用上升至1720萬澳元，相較於800萬澳元，這主要是由於人員成本、合規費用和基於股票的補償增加。截至2024年6月30日，公司持有現金及現金等價物590萬澳元，較去年同期的2210萬澳元下降，流動資產超過流動負債1060萬澳元。公司通過與Arena業務的5000萬澳元股權信貸協議和高達1000萬澳元的可轉換債券安排獲得了潛在資金。管理層相信，這些融資選項結合當前資源應能支持運營直到2025年8月，儘管公司在未來12個月繼續作爲持續經營的能力上存在顯著疑慮。
Incannex Healthcare在2024財年報告淨虧損1850萬澳元，而2023財年爲4880萬澳元。研發費用顯著增加至1290萬澳元，較去年的630萬澳元大幅提升，這主要是由於IHL-42X、IHL-675A和PSX-001臨牀試驗的推進。公司獲得了1140萬澳元的研發稅收激勵，較去年70萬澳元有所增加。一般和管理費用上升至1720萬澳元，相較於800萬澳元，這主要是由於人員成本、合規費用和基於股票的補償增加。截至2024年6月30日，公司持有現金及現金等價物590萬澳元，較去年同期的2210萬澳元下降，流動資產超過流動負債1060萬澳元。公司通過與Arena業務的5000萬澳元股權信貸協議和高達1000萬澳元的可轉換債券安排獲得了潛在資金。管理層相信，這些融資選項結合當前資源應能支持運營直到2025年8月，儘管公司在未來12個月繼續作爲持續經營的能力上存在顯著疑慮。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

獨立文件10  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Petros Pharmaceuticals
    PTPI
    -- 0.1350
    Quantum BioPharma
    QNTM
    -- 6.950
    TherapeuticsMD
    TXMD
    -- 1.010
    大自然藥業
    UPC
    -- 4.8500
    Shuttle Pharmaceuticals
    SHPH
    -- 0.404
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點